MEI Pharma Inc [NASDAQ: MEIP] slipped around -0.22 points on Tuesday, while shares priced at $2.78 at the close of the session, down -7.33%.
MEI Pharma Inc stock is now -11.75% down from its year-to-date (YTD) trading value. MEIP Stock saw the intraday high of $3.04 and lowest of $2.76 per share. The company’s 52-week high price is 9.00, which means current price is +90.41% above from all time high which was touched on 07/18/25.
Compared to the average trading volume of 1.26M shares, MEIP reached a trading volume of 5650894 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about MEI Pharma Inc [MEIP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MEIP shares is $22.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MEIP stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Laidlaw have made an estimate for MEI Pharma Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on July 23, 2024. While these analysts kept the previous recommendation, Wells Fargo raised their target price from $13 to $2. The new note on the price target was released on March 25, 2022, representing the official price target for MEI Pharma Inc stock. Previously, the target price had yet another drop from $6 to $2, while Stifel kept a Hold rating on MEIP stock. On March 25, 2022, analysts decreased their price target for MEIP shares from 4 to 1.
The Price to Book ratio for the last quarter was 0.95, with the Price to Cash per share for the same quarter was set at 0.62.
How has MEIP stock performed recently?
MEI Pharma Inc [MEIP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -42.68. With this latest performance, MEIP shares dropped by -46.44% in over the last four-week period, additionally plugging by 13.93% over the last 6 months – not to mention a rise of 13.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MEIP stock in for the last two-week period is set at 24.77, with the RSI for the last a single of trading hit 0.50, and the three-weeks RSI is set at 0.49 for MEI Pharma Inc [MEIP]. The present Moving Average for the last 50 days of trading for this stock 4.51, while it was recorded at 3.76 for the last single week of trading, and 2.94 for the last 200 days.
MEI Pharma Inc (MEIP) Capital Structure & Debt Analysis
According to recent financial data for MEI Pharma Inc. ( MEIP), the Return on Equity (ROE) stands at -89.74%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -68.80%, reflecting the company’s efficiency in generating profits from its assets. Additionally, MEI Pharma Inc’s Return on Invested Capital (ROIC) is -162.03%, showcasing its effectiveness in deploying capital for earnings.
MEI Pharma Inc (MEIP) Efficiency & Liquidity Metrics
Based on MEI Pharma Inc’s (MEIP) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
MEI Pharma Inc (MEIP) Efficiency & Liquidity Metrics
From an operational efficiency perspective, MEI Pharma Inc. (MEIP) effectively leverages its workforce, generating an average of -$1130714.29 per employee. The company’s liquidity position is robust, with a Current Ratio of 16.78% and a Quick Ratio of 16.78%, indicating strong ability to cover short-term liabilities.
Earnings analysis for MEI Pharma Inc [MEIP]
With the latest financial reports released by the company, MEI Pharma Inc posted 8.46/share EPS, while the average EPS was predicted by analysts to be reported at -1.79/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.26. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MEIP.
Insider trade positions for MEI Pharma Inc [MEIP]
There are presently around $8.13%, or 8.80%% of MEIP stock, in the hands of institutional investors.
